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Background: Current smoking is associated with type 2 diabetes mellitus and impaired glucose tolerance but its
association with the metabolic syndrome (metS), particularly with sufficiently sampled African American
representation, has not been clearly established.
Objective: To assess whether a) metS is associated with smoking; b) any increased risk of metS among smokers is
independent of body mass index (BMI) compared with non-smokers; c) smoking status is differentially associated
with the metS and its components across different ethnic groups.
Methods: Cross sectional analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) a community population-
based sample free of cardiovascular disease.
Results: Current smokers (N = 769) had higher risk of metS (odds ratio [OR, 95% confidence interval]: 1.4, 1.1-1.7)
versus never (reference, N = 2981) and former smokers (1.0, 0.8-1.1, N = 2163) and for metS components: high waist
circumference (WC) (OR:1.9, 1.2-2.1), low high density lipoprotein cholesterol (HDL-C) (1.5, 1.3-1.8), elevated plasma
triglycerides (TG) (OR:1.4, 1.2-1.7) as well as high C-reactive protein (CRP, an inflammatory marker) concentration
(OR: 1.6,1.3-2.0) compared to never and former smokers after adjustment for BMI. A smoking status by ethnicity
interaction occurred such that African American current and former smokers had greater likelihood of low HDL-C
than White counterparts.
Conclusions: This study found that smoking is associated with the metS and despite the lower BMI of current
smokers the prevalence of low HDL-C, elevated TG and CRP is higher among them than among non-smokers.
African Americans generally have higher HDL-C than Whites but smoking wipes out this advantage.
Multi-Ethnic Study of Atherosclerosis (MESA) ClinicalTrials.gov Identifier: NCT00005487
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Tobacco use continues to be the leading global cause of
preventable death. It kills nearly 6 million people and
causes hundreds of billions of dollars of economic dam-
age worldwide each year [1]. Cigarette smoking causes
about 1 of every 5 deaths in the United States each year
[2]. The leading causes of death from smoking are car-
diovascular diseases (1.69 million deaths), chronic
obstructive pulmonary disease (0.97 million deaths) and* Correspondence: ivan.berlin@psl.aphp.fr
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reproduction in any medium, provided the orlung cancer (0.85 million deaths) [3]. Smoking cessation
leads to reduced mortality, in particular, in patients with
coronary heart disease [4]. Active smoking increases the
prevalence and incidence of type 2 diabetes mellitus [5-
8] and glucose intolerance [9] as does secondhand
smoke exposure [9,10].
Smoking is associated with increased likelihood of low
HDL-C [11-13]; and has been suggested to be associated
with insulin resistance [14-16] and increased level of in-
flammatory markers (e.g., CRP) [17,18]. Some studies
have assessed the smoking – metS relationship [19-24]
but we are not aware of data on the association of smok-
ing status with the clustered metabolic risk factorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as increased TG, reduced HDL-C concentrations,
increased blood pressure (BP) and impaired fasting glu-
cose (IFG) in multi-ethnic groups.
It is well known that cigarette smokers weigh less than
non-smokers [25-30] and their age and gender adjusted
body mass index (BMI) is on average 1 kg/m2 less than
that that of non-smokers [31]. Despite this, compared to
non-smokers, current smokers are more likely to have
abdominal type obesity [24,26,29]. The lower BMI of
smokers compared to non-smokers raises questions
regarding the impact of smoking on cardiovascular
disease (CVD) risk factors such as the metS, its compo-
nents and inflammatory markers such as CRP [32].
Therefore the aims of this cross sectional analysis were
a) to assess metabolic syndrome, its components and a
CVD risk factor CRP among smokers compared to
former and never smokers; b) to test the contribution of
BMI on the associations between smoking status and
these risk factors; and c) to evaluate whether the asso-
ciation of smoking status with these risk factors varies
across ethnicity and secondarily by gender.
Methods
Study population
The Multi-Ethnic Study of Atherosclerosis (MESA) is a
multicenter cohort study of participants recruited be-
tween 2000 and 2002; details regarding recruitment and
design have previously been published [33]. Briefly, it is
a population-based sample of men and women aged 45–
84 who identified themselves as non-Hispanic White,
African-American, Hispanic or Chinese American and
were free of clinically apparent cardiovascular disease.
Participants were recruited from six US communities:
Baltimore City and County, MD, Chicago, Ill, Forsyth
County, NC, Los Angeles County, CA, northern Man-
hattan and the Bronx, NY, and St Paul, MN. The institu-
tional review boards of all participating centers approved
the study and all participants gave informed consent.
From the total sample (N = 6814) we excluded partici-
pants with missing smoking status or missing other data
precluding the characterization of metabolic syndrome.
We excluded participants with diabetes, or taking medi-
cines for diabetes or having fasting glucose >125 mg/dL,
and those whose diabetes status was unknown. Thus,
the study population consisted of 5913 participants:
37.6% non-Hispanic Whites, 23.6% African Americans,
10.7% Chinese Americans and 28.1% Hispanics.
Measures
At baseline, questionnaires were used to obtain informa-
tion about demographics, socioeconomic status, medical
history and medications. Waist circumference at the um-
bilicus was measured to the nearest 0.1 cm using a steelmeasuring tape. Height and weight was measured by a
stadiometer and calibrated scale. Body mass index was
calculated from height and weight as kg/m2. Resting
blood pressure was measured three times with partici-
pants in a seated position with a Dinamap model Pro100
automated oscillometric sphygmomanometer (Critikon);
the average of the last two measurements was used in
the analysis. Triglycerides, HDL-C, blood glucose, and
plasma insulin concentrations were measured from
blood samples obtained after a 12-hour fast. Metabolic
syndrome was classified using the updated Adult Treat-
ment Panel III (ATP III) definition [34] as three or more
of the following: High WC (WC> 102 cm for men and
WC> 88 cm for women); elevated TG (≥150 mg/dL);
low HDL-C (men< 40 and women< 50 mg/dL); ele-
vated blood pressure (systolic blood pressure ≥130 or
diastolic blood pressure ≥85 mmHg or use of medica-
tions for hypertension); and elevated fasting glucose
(≥100 mg/dL). For Chinese Americans we used the
International Diabetes Federation (IDF) cut off point for
high WC: >90 cm for men and >80 cm for women [35].
We defined impaired fasting glucose as between
100 mg/dL and125 mg/dL. Insulin resistance was esti-
mated by homeostasis model assessment of insulin re-
sistance (HOMA-IR), calculated according to the
formula (insulin (mU/I)*(glucose [mg/dL]0.055)/22.5).
The top quartile value was used as cutoff point to deter-
mine insulin resistance. CRP was measured using the
BNII nephelometer (N High-Sensitivity CRP); intra-assay
coefficient of variation for CRP range from 2.3 to 4.4%
and inter-assay coefficients of variation range from 2.1
to 5.7% [36]. Elevated CRP was defined as CRP ≥ 5 mg/L
[37]. Physical activity was measured by using a detailed,
semiquantitative questionnaire adapted from the Cross-
Cultural Activity Participation Study [38]. The sum of
minutes spent in all activity types was multiplied by the
metabolic equivalent (MET) level and physical activity
level was expressed as min/week*MET [39].
Never smoking was defined as lifetime consumption of
less than 100 cigarettes (N = 2981). There were 2163
former smokers. Among them, 2105 quit smoking ≥ 1
year earlier and 58 between 30 days and 1 year. These
latter were added to the group of former smokers. The
mean pack years was 21 (SD= 25) for former and 27
(SD= 32) for current smokers. Data were analyzed
according to smoking status and not according to pack
years for two reasons. First, use of pack years does not
provide information about former smoking status and
can erase the effect of quitting. Second, a body of
tobacco research has suggested that smoking induced
disease risk, in particular cardiovascular risk, is
dependent to a greater degree on the duration of expos-
ure, and less dependent on the amount smoked (i.e. low
number of cigarettes per day or occasional cigarette
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risk) [40].
Alcohol use was screened with the following questions:
“Have you ever consumed alcoholic beverages?” and “Do
you presently drink alcoholic beverages?” and partici-
pants were classified as current, former or never users.
Data analysis
ANOVA and chi-square tests were used to examine the
characteristics of the study participants by smoking sta-
tus (never, former and current smoker). Logistic regres-
sion models were used to examine the association of
smoking status with CVD risk factors with and without
adjustment for BMI. The following factors were included
as covariates: age, gender, ethnicity, site, household in-
come, alcohol consumption, physical activity, lipid low-
ering and antihypertensive drugs and education.
Interactions of race/ethnicity and gender with smoking
status were tested for each CVD risk factor. Data are
reported as frequencies and odds ratios (OR) with 95%
confidence intervals (CI) if otherwise not indicated. Sig-
nificance level was set at p≤ 0.05.
Results
Current smokers were younger, and reported less house-
hold income and education than never smokers. Current
smoking was the most frequent among non-Hispanic
Whites and the less frequent among Chinese Americans.
Use of antihypertensive medications or lipid lowering
drugs were less frequent among current smokers than
among never or former smokers and they reported more
moderate/vigorous physical activity.
The prevalence of ATP-III metS was similar between
the three smoking status groups. However, when looking
at the individual metS components, the prevalence of all
risk factors except IFG and HOMA-IR were significantly
different between smokers, former smokers and never
smokers. In particular, while among current smokers
high WC, above normal BMI (overweight/obesity), and
elevated BP were less frequent, current smokers had
higher prevalence of low HDL-C, high plasma TG and
elevated CRP (Table 1).
Table 2 shows the associations of smoking status with
metS and its components with and without adjustment
for BMI. Smoking status was significantly associated
with the presence of metS or high WC only in the mod-
els adjusted for BMI. Without adjustment for BMI,
HOMA-IR was significantly less frequent among current
smokers than among former or never smokers but the
differences disappeared after adjustment for BMI
(Table 2).
The significant association of low HDL-C, elevated TG
and elevated CRP with smoking status did not change
after adjusting for BMI (Table 2).Table 3 shows the significant interactions of smoking
status with ethnicity and gender. There was a significant
interaction of smoking status with ethnic groups for
HDL-C. Among African Americans both former and
current smokers were more likely than never smokers to
have low HDL-C while only current smokers were more
likely to have low HDL-C among non-Hispanic Whites
or Hispanics. Thus, the significant smoking status by
ethnicity interaction results from the higher likelihood
to have a higher prevalence of low-HDL-C among
former smoker African Americans than among non-
Hispanic Whites or Hispanics.
There was no statistically significant difference in ele-
vated TG or high WC by smoking status neither among
males nor among females. However, when adjustment
was made for BMI, male current and former smokers
were more likely to have high WC than never smokers.
These associations were not statistically significant
among females.
Discussion
This study found that current smoking is associated with
the metS and despite the lower BMI of current smokers
the prevalence of high WC, low HDL-C, elevated TG is
higher than among non-smokers. The prevalence of high
CRP, an inflammatory marker associated with CVD risk
[32] was also higher among current smokers compared
to never or former smokers. The only difference which
occurred between smokers of different ethnic origin
concerned low HDL-C: the highest risk for low HDL-C
was observed among African American current and
former smokers.
At any age, both male and female smokers have lower
BMI than non-smokers or former smokers [25,27,28,30].
Thus the question arises whether BMI influences or not
the presence of metS and its components among per-
sons of different smoking status: never, former or
current smoking. When adjusted for BMI, we found that
smokers were at higher risk of metS and high WC. Al-
though smokers of this sample seemed to have less fre-
quently insulin resistance than non-smokers (never or
former smokers), this apparent benefit was simply
related to the confounding effect of their lower BMI. Al-
though adjustment for BMI had no influence on the
prevalence of elevated blood pressure and impaired fast-
ing glucose concentration, it revealed that the metS is
more frequent among current than among former or
never smokers, and that the high WC is associated with
current smoking. Smoking seems to be associated with
low HDL-C, high TG and CRP independently of BMI.
Conflicting data exist about the smoking status – metS
relationship. Data from the Third National Health and
Nutrition Examination Survey (NHANES III) showed
that when adjusted for all modifiable lifestyle factors
Table 1 Characteristics of the study population by smoking status
Never smoker Former smoker Current smoker P-value
N=2981 N=2163 N=769
Demographics
Age (years) 61.8 (10.6) 63.2 (9.9) 57.8 (9.2) <0.001
Gender-Males (%) 37.7 56.9 50.8 <0.002
Race/ethnicity (%) <0.001
Non-Hispanic White 36.4 50.0 36.8
Chinese American 17.7 6.1 4.7
African American 23.3 26.1 36.3
Hispanic 22.5 17.9 22.2
Education (%) <0.001
High school or less 36.5 29.9 38
Some college 24.8 30.8 37.8
Bachelor or graduate 38.7 39.3 24.2
Household income level per year (%) <0.001
<$25000 31.9 26.0 31.5
>$25000 and< $50000 28.2 27.7 32.8
>$50000 and< $75000 16.4 18.6 18.4
>$75000 23.4 27.7 17.3
Medications
Use of antihypertensive medications (%) 30.7 30.4 23.4 <0.001
Use of lipid lowering medications (%) 14.1 16.3 10.7 <0.001
Behavioral variables
Alcohol use (%) <0.001
Never 32.4 6.2 8.2
Former 18.2 28.4 22.5
Current 49.4 65.4 69.3
Physical activity (min/week-MET) 5604 (5625) 5857 (6095) 6631 (6662) <0.001
First quartile <2055 26.0 23.2 25.6 <0.001
2nd quartle (2055–4125) 25.4 26.8 19.0
3rd quartile (4125–7545) 24.8 25.7 23.9
4th quartile (>7545) 23.8 24.3 31.5
Cardiometabolic profile (%)
ATP-III Metabolic syndrome 26.5 26.3 27.3 0.9
Metabolic syndrome components
High WC 58.2 53.5 51.6 <0.001
Elevated BP 50.9 54.8 44.0 <0.001
Low HDL-C 34.1 31.4 42.0 <0.001
Elevated TG 27.6 26.1 32.3 0.005
Impaired fasting glucose 15.7 16.3 14.7 0.6
Insulinresistance (HOMA-IR) 25.5 26.6 23.6 0.3
Elevated CRP 18.1 19.5 24.0 0.001
Normal weight (BMI< 25) 32.7 27.3 30.9 <0.001
Obese (BMI> 29.9) 29.0 31.6 28.2 0.08
Data are means (SD) or percentages.
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Table 2 Effect of body mass index (BMI) on the association of cardiovascular disease risk factors with smoking status













Metabolic syndrome reference 1.0 (0.9-1.2) 1.1 (.9-1.3) 0.5 reference 1.0 (0.8-1.1) 1.4 (1.1-1.7) 0.03
Metabolic syndrome components
High WC reference 1.1 (0.9-1.2) 0.9 (0.7-1.1) 0.2 reference 1.1 (0.9-1.3) 1.6 (1.2-2.1) 0.004
Elevated BP reference 1.1 (0.9-1.2) 0.9 (0.7-1.0) 0.09 reference 1.0 (0.9-1.2) 0.9 (0.8-1.1) 0.5
Low HDL-C reference 1.0 (0.9-1.1) 1.3 (1.2-1.6) 0.001 reference 1.0 (0.8-1.1) 1.5 (1.3-1.8) <0.001
Elevated TG reference 1.0 (0.9-1.1) 1.1 (1.1-1.6) 0.009 reference 1.0 (0.8-1.1) 1.4 (1.2-1.7) <0.001
Impaired fasting glucose reference 1.0 (0.8-1.1) 1 (0.8-1.2) 0.9 reference 0.9 (0.8-1.1) 1.1 (0.9-1.4) 0.2
Insulin resistance (HOMA-IR) reference 1.1 (0.9-1.2) 0.8 (0.7-0.98) 0.02 reference 1 (0.9-1.2) 1.0 (0.8-1.2) 0.9
Elevated CRP reference 1.2 (1.03-1.4) 1.3 (1.1-1.6) 0.01 reference 1.2 (0.98-1.4) 1.6 (1.3-2.0) <0.001
Adjusted for age, gender, ethnicity, site, household income, alcohol consumption, physical activity, lipid lowering and antihypertensive drug and education.
OR are shown with one decimal for clarity.
Data are odds ratios (OR) and (95% confidence intervals).
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associated with increased risk of metS when adjusted for
BMI for both men and women [19]. In a Korean popula-
tion, more than 20 pack-year smoking has been found to
be associated with a 1.9 fold risk of BMI adjusted metS
[20]. A recent cross sectional study did not find an asso-
ciation between smoking status and metS [21] but no
adjustment was made for BMI. Geslain-Biquez et al. [22]
reported that the frequency of metS was higher among









Males reference 1.0 (0.8-1.3) 1.4
Females reference 1.0 (0.8-1.2) 1.3
Interaction of gender with smoking status
High WC*
Males reference 1.2 (1.0-1.5) 1.1
Females reference 1.0 (0.9-1.3) 0.8
Interaction of gender with smoking status
Low HDL-C**
Non-Hispanic Whites reference 0.8 (0.7-1.0) 1.3
African Americans reference 1.5 (1.1-1.9) 1.6
Hispanics reference 1.1 (0.8-1.5) 1.5
Chinese Americans reference 0.7 (0.4-1.2) 1.2
Interaction of ethnicity with smoking status 0.05
*Adjusted for age, ethnicity, site, household income, alcohol consumption, physical
**Adjusted for age, gender, site, household income, alcohol consumption, physical
OR are shown with one decimal for clarity.
Data are odds ratios (OR) and (95% confidence intervals).this sample there was no difference in BMI between
smokers and non-smokers showing that at equal BMI
smoking is associated with increased prevalence of metS.
To our knowledge only two prospective studies reported
about incident metS and smoking status. Carnethon
et al. [23] found when analyzing data of the CARDIA
study that baseline smoking status did not predict inci-
dent metS during an average follow up of 13.6 years but
there is no information what was the percent of smokers
who became former smokers which potentially couldonents with smoking status by gender and race









(1.1-1.8) 0.055 reference 1.0 (0.8-1.2) 1.5 (1.1-2.0) 0.006
(0.9-1.7) 0.3 reference 1.0 (0.8-1.2) 1.4 (0.99-1.8) 0.06
0.02 0.04
(0.9-1.4) 0.1 reference 1.3 (1.0-1.7) 2.2 (1.5-3.3)<0.001
(0.6-1.0) 0.08 reference 1.0 (0.8-1.3) 1.2 (0.8-1.8) 0.7
<0.001 <0.001
(1.0-1.7) 0.02 reference 0.9 (0.7-1.0) 1.5 (1.1-2.0) 0.001
(1.1-2.2) 0.007 reference 1.4 (1.1-1.9) 1.8 (1.3-2.6) 0.001
(1.0-2.2) 0.01 reference 1.1 (0.8-1.4) 1.6 (1.1-2.3) 0.07
(0.6-2.5) 0.3 reference 0.7 (0.4-1.1) 1.1 (0.5-2.3) 0.3
6 0.026
activity, lipid lowering and antihypertensive drug and education.
activity, lipid lowering and antihypertensive drug and education.
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demonstrated ethnic differences in developing metS, it
did not report on ethnicity by smoking status interaction
[23]. In a Turkish population during a mean follow up of
5.9 years smoking was inversely associated with WC and
among women smoking reduced the risk of metS by
half; however this “protective” effect of smoking on metS
was not accompanied by a subsequent reduction in cor-
onary heart disease or all-cause mortality [24].
In the current sample the multivariate analysis showed
that smoking status was not associated with blood pres-
sure. The relationship between smoking and blood pres-
sure is controversial some studies reporting higher
others lower blood pressure [41]. However, compared to
non-smokers, smoking has been more consistently
found to be associated with lower systolic and diastolic
blood pressure in Nord-American [17], European [24,42]
and Asian populations [43,44]. The lower blood pressure
found among smokers may be associated with their
lower BMI as shown in the present study.
In the present study we did not find in the multivariate
analysis that HOMA IR, a proxy measure of insulin re-
sistance, or fasting plasma glucose concentration were
associated with smoking status. It has been suggested
that the insulin resistance syndrome is the key player be-
tween cigarette smoking and CVD [15]. This hypothesis
is mainly based on acute human lab studies [14,16] and
on the considerations that smoking may result in
reduced skeletal muscular blood flow, vascular changes
and abdominal type adiposity, all potentially associated
with reduced insulin-mediated glucose uptake and insu-
lin sensitivity. However, a large cross sectional study did
not confirm that active smoking was associated with
increased insulin resistance [45]. Further studies are
needed to explore specifically the smoking - insulin re-
sistance relationship.
Because of the demonstrated ethnic and gender differ-
ences in the prevalence of the metS and its components
[46-50], this study tested whether the association of the
metS and its components with smoking varied by ethni-
city and secondarily by gender. There was no apparent
evidence that the studied CVD risk factors associated
with smoking varied significantly by ethnic groups ex-
cept the finding that low HDL-C was more prevalent
among African American current and former smokers
compared with non-smokers and their counterparts in
other ethnic groups. African Americans generally have
higher HDL-C than non-Hispanic Whites. According to
the present data smoking is associated with reduction in
(the protective) HDL-C in African Americans and may
increase by this their CVD risk more than among non-
Hispanic Whites. This finding strongly suggests that in-
tensive specific interventions should be targeted among
African American smokers and former smokers toimprove their smoking induced negative lipid profile to
reduce the burden of CVD risk.
The prevalence of metS components and CRP did not
differ between males and females according to smoking
status suggesting a similar risk factor level among men
and women smokers. The unfavourable association of
current and former smoking with high WC after adjust-
ment for BMI became significant only among males. It is
not clear whether this differential association with gen-
der concerning only WC was related to the intensity of
exposure to tobacco or to other factors. Future studies
are needed to examine the plausible causes.
There are several limitations to this study. This was a
cross sectional analysis; smoking status was based on
self-report and no biological validation approaches such
as expired air carbon monoxide or saliva/plasma/urine
cotinine concentrations were used to confirm self-report
of smoking status. BMI is inversely related with the
number of cigarettes smoked per day [26]. It has also
been shown that HDL-C levels decrease on a dose-
dependent way with increases in the number of cigar-
ettes smoked per day [11]. It would have been important
to analyze if, among current smokers, these dose–re-
sponse relationships exist for other metS components
and whether they are similar or not across the different
ethnic groups or gender. Unfortunately, this could not
have been done because of the low power for these ana-
lyses: among current smokers cigarettes per day categor-
ies by ethnic groups or by gender yielded very few cell
numbers. A major limitation is that the cross sectional
nature of the data did not allow assessing prospectively
changes in metS and its components in particular
among smokers who quit.
Because smokers cite control of body weight as a rea-
son to continue smoking [51-55] and the tobacco indus-
try reinforces this notion through advertising [56] it is
important to look at the effect of the lower body weight
associated with current smoking on CVD risk factors
such as metS components and inflammatory markers.
This study found that lower BMI of current smokers
does not improve their lipid profile and the inflamma-
tory marker CRP. This can partially explain that lower
BMI of smokers does not protect against developing
smoking related cardiovascular disorders.
In conclusion, smoking is associated with the metS
and despite the lower BMI of smokers compared to
non-smokers the risk profile of components of metS
with demonstrated association with CVD risk is main-
tained. Among African Americans who generally have
higher HDL-C than Whites, smoking nullifies this ad-
vantage. Current smoking may differentially be asso-
ciated with metS components in specific ethnic groups
or among males potentially leading to a differentially
increased CVD risk.
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